Compare Constellation Energy Corporation (CEG) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs DexCom, Inc. — how do they compare? Constellation Energy Corporation trades at $282.83 (market cap $98.63B), while DexCom, Inc. trades at $89.17 (market cap $33.79B). The key difference: Constellation Energy Corporation is far larger — about 2.9× DexCom, Inc.'s market cap, and Constellation Energy Corporation pays a 0.61% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CEG | DXCM | |
|---|---|---|
Market Cap | $98.63B | $33.79B |
Sector | Energy | Health |
52-Week High | $403.95 | $89.53 |
52-Week Low | $236.50 | $54.84 |
Enterprise Value | $122.63B | $33.24B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) is trading at $281.84, up 4.22% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS of $2.55 beating expectations by 11.4%, and raised 2026 guidance. Recent news highlights nuclear power contracts with major tech companies driving growth. Technical indicators show bullish momentum with support at $277 and resistance at $282.
CEG presents a compelling investment case with strong earnings momentum, AI-driven power demand tailwinds, and 70% analyst buy ratings. Risks include execution of nuclear capacity expansion and potential regulatory changes. The consensus price target of $332.13 suggests 18% upside potential from current levels.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
